Ginkgo Posts Narrower Q3 Loss, Lands First Autonomous Lab Sale to Pharma Giant Novo
DNA sits 85% above its 52-week low of $5.37.
Summary
Ginkgo reported Q3 2026 revenue of $28M, down 6% from $29M a year ago but up from $20M in Q2, and cut its GAAP net loss from continuing operations to $41M from $73M. Adjusted EBITDA improved to -$22M from -$53M, and cash burn was $27M for the quarter. The balance sheet showed $285M in cash, equivalents and marketable securities at September 30. The bigger story is commercial: Ginkgo signed its first autonomous lab sale to a top-tier pharma, Novo, at Novo's new Waltham, Massachusetts R&D site, and won an ARPA-H GIVE subcontract worth up to $17.5M to put its RAC and Catalyst systems into RNA-medicine manufacturing. Management reaffirmed full-year 2026 cash burn guidance of $125M-$150M. The company is pitching its Cloud Lab and autonomous lab equipment as an onshore alternative to overseas CROs, with 22 ADME customers signed in Q3, 20 of them first-time Ginkgo customers.
At the time of this announcement, DNA was trading at $9.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $670.7M. The 52-week trading range was $5.37 to $18.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.